For example, it was shown that SGLT2 inhibitor suppresses hepatocellular cancer (HCC) in-vitro growth through blockage of glucose influx-induced β-catenin action, which is a pro-oncogenic protein [234]. This evidence concerns the gene SLC5A2 and hepatocellular carcinoma.